Dyslipidemia Drug Indications
Comparative chart of single and combination treatment options indicating which lipids can be targeted for dyslipidemias.
Dyslipidemia
Case Series: Insulin Infusions for Severe Hypertriglyceridemia With COVID-19
Findings of the review showed that continuous insulin infusion, coupled with standard oral lipid lowering therapies, successfully treated the hypertriglyceridemia.
Managing the Interplay of Familial Hypercholesterolemia and COVID-19
About 90% of those with familial hypercholesterolemia have not been diagnosed or treated for it, leaving them more vulnerable for COVID-19 infection and its complications.
Inclisiran Safe, Effective in Reducing LDL-C in Patients With Familial Hypercholesterolemia or ASCVD
Researchers conducted a patient-level pooled analysis from phase 3 trials of inclisiran in patients with familial hypercholesterolemia or ASCVD.
Thyroid Functioning Biomarkers May be Related to Blood Lipid Profiles
Observational studies using Mendelian randomization have demonstrated a causal relationship between normal range thyroid stimulating hormone (TSH) levels and blood lipids. In this featured study, researchers attempt to show a causal relationship between thyroid function and lipids.
Dysglycemia Linked With Advanced Thyroid Cancer in Those Aged 55 Years or Older
Study authors performed a retrospective review of a thyroid cancer cohort to evaluate the association between metabolic health and severity of thyroid cancer.
Helicobacter pylori Eradication Associated With Reduced Risk of Dyslipidemia
A team of investigators conducted a large retrospective, cohort study to assess whether a longitudinal link exists between H pylori infection and the risk of developing dyslipidemia.
Lipoprotein Apheresis Treatment for Hyperlipoproteinemia and Familial Hypercholesterolemia
Lipoprotein apheresis was associated with reduced concentrations of LDL-C and Lp(a) in patients with hyperlipoproteinemia (a) and FH on a maximally tolerated lipid-lowering regimen.
Triglyceride-Rich Lipoprotein Metabolism Drives Complications in FCS and MCS
The objective was to study the incidence of acute pancreatitis, ischemic cardiovascular disease, and diabetes in hyperchylomicronemic patients with FCS and MCS compared with the general population.
Evinacumab Lowers LDL Cholesterol in Refractory Hypercholesterolemia
In this phase 2 trial, patients with hypercholesterolemia and clinical atherosclerotic cardiovascular disease were recruited from 85 sites across 20 countries.
-
Loading...
-
Loading...
Next post in Cardiovascular and Metabolic Disorders
